TrialNaunyn-Schmiedeberg's archives of pharmacology2025

Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers.

Friedrich Schulze et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.